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Research communicationClinical genomic research faces increasing challenges in establishing participant privacy and consent process-
es that facilitate meaningful choice and communication capacity for longitudinal and secondary research
uses. There are an evolving range of participant-centric initiatives that combine web-based informatics
tools with new models of engagement and research collaboration. These emerging initiatives may become
valuable approaches to support large-scale and longitudinal research studies. We highlight and discuss
four types of emerging initiatives for engaging and sustaining participation in research.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Despite increasing capabilities in technology and analytic perspec-
tives, translational researchers still face familiar challenges in generat-
ing successful trials and studies (Collins, 2011). Both in the US and
internationally, slow recruitment and limited retention of research par-
ticipants can hinder the research process (Sung et al., 2003; Center for
information and study on clinical research participation (CISCRP),
2012; Gottweis et al., 2011). Participation and engagement are further
limited within some marginalized socioeconomic or cultural groups
(Gottweis et al., 2011; Bowen and Penchaszadeh, 2008; Wynia and
Gamble, 2006; James et al., 2008; Bussey-Jones et al., 2010). In parallel,
human subjects' research regulations in the U.S. and E.U. pose ethical
and public relations challenges (Silverman et al., 2001; Fullerton and
Lee, 2011), with many researchers and institutions preferring to use
de-identified datasets to limit responsibilities and liabilities. Against
these common research challenges are evolving new modes of data
sharing and collaboration, including research networks and increasing-
ly coordinated access to large-scale resources such as biobanks or clini-
cal data warehouses. These innovations also increase the complexity of
coordination, accountability, preference management, and researcher–
participant communication (Fullerton et al., 2010; Heeney et al., 2011;
Kaye et al., 2009; Mascalzoni et al., 2008; McGuire et al., 2011;
Ludman et al., 2010; Harmon, 2010). The ability to leverage communi-
cations technologies such as social media may ameliorate some of the
traditional roadblocks to broad patient participation in health care, 850 Republican St, Box
9; fax: +1 206 685 7515.
-NC-ND license. (Trinidad et al., 2011), and similar approaches provide new models
for engaging participants in the research process and facilitating
researcher–participant collaboration. In clinical settings, decision aids
have been evolving to support patients' self-education and decision
support as components of their participation in therapeutic paths, and
these methods can now also play a part in research (Swan, 2009). As
these technologies and challenges intersect, a range of public/private
participant-centric initiatives illustrate how information tools can expe-
dite translational research. We highlight four emerging types of initia-
tives that illustrate evolving approaches of participant engagement
and theuse of informatics-based tools to expedite translational research.
2. What are patient centric-initiatives?
Participant-centric initiatives (PCI) are tools, programs, and projects
that empower participants to engage in the research process and, in
many cases, can differentiate between a range of diverse preferences
and needs. Although current U.S. and E.U. human subjects' regulations
permit secondary research on de-identified data and biosamples with-
out further participant contact or consent (Fullerton and Lee, 2011),
cautionary tales demonstrate that people feel that they are marginal-
ized if they are excluded from the research process (Ludman et al.,
2010; Harmon, 2010). For example, some research participants are
not concerned about what happens to biosamples that have been
collected from them for research, yet many participants have concerns
about their lack of involvement in data sharing for secondary research
use (Trinidad et al., 2011, 2010; Brase, 1998). Diverse preferences
need dynamic tools to manage them, and one-size fits all approaches
such as waivers of consent or “broad consent” are increasingly under
significant critique (Simon et al., 2011; Sheehan, 2011; Hansson et al.,
Fig. 1. Example ofmodes of engagement and communication for patient centric initiatives.
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can make enquiries about their level of engagement in studies.
Given this complex social climate of regulatory challenges, partici-
pant desire for greater control, and advancing scientific needs, our cur-
rent regulations may provide a baseline for research practice, above
which methods that support greater connection with participants may
be beneficial. PCI offer the potential to communicate with participants
and in some instances, mediate participants' active control and choice
within diverse research contexts. Conceptually, PCI facilitate a shift
from a negative right to privacy, where researchers protect identity by
promising anonymity or de-identification, to a positive right to privacy,
where participants are given active control over who sees their data
and in what contexts (Warren and Brandeis, 1890). Although further
research is needed to demonstrate the impact of increased participant
control afforded by PCI on recruitment and retention, we can anticipate
that the shift to more participant control will address some concerns
expressed by privacy advocates about data used for research (Trinidad
et al., 2010). Furthermore, where some disenfranchised groups have
been historically mistreated at the hands of researchers, the hypothesis
is that increased control and enhanced communication opportunities
will improve transparency to the point of encouraging participation
(Bowen and Penchaszadeh, 2008; Wynia and Gamble, 2006; James et
al., 2008; Bussey-Jones et al., 2010).
A growing evidence base of patient-centric health initiatives,
decision-support research (Brase, 1998), and participant managed re-
search enterprises provides a range of alternative models from which
to learn (Genetic Alliance, 2012; Sharp and Landy, 2010; Kaye et al.,
2012; Corradetti and Mascalzoni, 2012; Weitzman et al., 2011;
Wicks et al., 2010). In two recent international “state of the science”
meetings, emerging tools for participant-centered informatics ap-
proaches used in research-based initiatives were discussed (Kaye et
al., 2012; Corradetti and Mascalzoni, 2012). In light of these emerging
tools, we created a framework to characterize four approaches uti-
lized within the tools with some tools incorporating more than one
approach (Fig. 1).
There are many PCI tools that directly contribute to research but
which fall outside of the criteria of this paper because they focus primarily
on empowering patients in their medical care. Examples include social
networking tools like Inspire.com and TuDiabetes (Wicks et al., 2010),
and participant-driven survey databases, such as CureTogether.com.
These tools contain large amounts of detailed personal data and represent
a resource for researchers to discover new research questions,find poten-
tial participants, and analyze the effectiveness of treatments. However,
these tools aimprimarily to empowerpatients in theirmedical care rather
than the research process. Our review is by no means exhaustive, but
rather an analysis of promising initiatives that offer the research commu-
nity several options for consideration.
2.1. Finding the engaged participant through intermediation:
participant–researcher ‘matchmaking’ tools
A range of potential factors may affect consideration of participation
in research, including prior participation in research and existing rela-
tionships with researchers, involvement of trusted leaders, and trust
in the organization (Gottweis et al., 2011; Bowen and Penchaszadeh,
2008; Wynia and Gamble, 2006; James et al., 2008; Bussey-Jones et
al., 2010). Although a majority of US residents (77%) say that they
would consider becoming involved in a research trial, only 10% of
those eligible to participate do so (Center for information and study
on clinical research participation (CISCRP), 2012). Many are not aware
of research opportunities (unpublished results, NWABR 2012). Europe-
an residents vary considerably in consideration of contribution of data
or samples to a biorepository for research purposes, with “93% of
Icelanders and 82% of Norwegians could imagine providing information
to a biobank, but only 25% of Latvians or 35% of Austrians are likely to do
so” (Gottweis et al., 2011). Some common barriers to recruitmentinclude lack of participant incentives, privacy concerns, complex and
confusing consent forms, differences in cultural norms, and lack of
public knowledge about the potential for participation. One possible solu-
tion is more active facilitation of connections between willing volunteers
and searching researchers, and enhanced communication structures that
support these potential relationships. Matchmaking tools do so by acting
as intermediators that draw together researchers and participants. For
example, participant-driven clinical registries, such asResearchMatch.org,
TrialX.com, and EmergingMed.com enable willing volunteers to enter
personal information (e.g., age, sex, conditions) and use this information
to find researchers in need as well as clinical trials seeking participants.
Currently, the effectiveness of such registry approaches depends
upon the study type (Weng et al., 2010). Traditional recruitment
methods, such as direct use of hospital data warehouses, are still ben-
eficial particularly if the participant inclusion criteria are well defined
or the study requires complex exclusion criteria. For example, a study
may require participants to be diabetic, with hemoglobin A1C values
between 6.5% and 8.0%, have pre-existing ischemic vascular disease,
not use insulin therapy, and have a certain requirement for glomeru-
lar filtration rate. At present it will be difficult for participant-driven
clinical registries to match this level of specificity, though tools like
EmergingMed.com, are addressing this problem by offering defined
and structured data definition and query options for cancer patients
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adoption by researchers and volunteers alike are contributing to richer
data resources, and are demonstrating the potential of suchmatchmak-
ing tools for overcoming recruitment bottlenecks in limited domains,
though a comprehensive evaluation of the effectiveness of these tools
across a range of demographic and disease types is still nascent.
2.2. Engagement through direct participant benefits:
‘Direct-to-consumer’ tools
Direct-to-consumer (DTC) tools offer individuals highly personal-
ized information as a proposed direct benefit of participation. For ex-
ample, established web-based DTC genetic testing companies, such as
23andMe.com or deCODEme.com seek to empower and promote
identity perception for individuals by supplying them with personal
genotype and phenotype information that may inform their personal
health decisions (Nordgren, 2012). The social interactions between
DTC companies and their customers are not without controversy, as
the promise of this form of consumer-focused health decision making
has to date managed to avoid either the predicted dire consequences
of a excessively worried public, or the proposed swell of empowered
and activated patients (Nordgren, 2012; Cecile et al., 2010). What the
DTC companies have enabled beyond personalized information is the
increased ability to facilitate participation in research. The research
arm of 23andMe, ‘23andWe’, notifies members of research opportuni-
ties enabled through more personalized matching of studies than
ResearchMatch through an extensive set of structured surveys about
their phenotypic traits. By connecting those self-reports to corre-
sponding genotypes, 23andWe can produce publishable study results,
and within days can verify other published results (Tung et al., 2011;
Wicks et al., 2011). To help drive their research arm, 23andMe
created condition-specific member communities (e.g., Parkinson's,
sarcoma, pregnant women). By joining, members receive free genetic
testing and involvement in the community forum. For example, the
“Roots into the future” community is an up-and-coming community
that offers 10,000 African Americans free genetic testing in return
for completing surveys. 23andWe's model leverages individuals' will-
ingness to participate in research and rewards their participation
with information people value. Given the amount of genetic informa-
tion that 23andMe can gather through this approach to participant
engagement, it is reasonable to assume that they have the potential
to produce many more substantial findings.
Like 23andMe, the health social network PatientsLikeMe.com started
as an organization that provided a service to people curious about their
health and frustrated with the slow progress of traditional research.
PatientsLikeMe.com has a substantial research arm and has great poten-
tial to conduct studies faster and cheaper than existing models (Tung
et al., 2011). For example, analysis of data reported by people with
amyotrophic lateral sclerosis (ALS) who experimented with lithium
carbonate reached the same conclusion as traditional randomized trials
(Wicks et al., 2011), indicating the potential for such communities to
conduct valuable studies. PatientsLikeMe.com also offers a comprehen-
sive clinical trial finder and various health tracking tools, making the
site a rich source of data. PatientsLikeMe.com asks all researchers to
first contact their partnership team before allowing researchers to use
the data for research or to use the site to recruit participants in their
studies. Once the partnership team gives permission, researchers can
specifically search for users who fit their study criteria. The referral
rates are high, making PatientsLikeMe.com an attractive and viable
option for populating studies.
2.3. Participant control through choices: tools for ‘dynamic negotiation’
between researchers and participants
DTC companies seek to offer something that many research institu-
tions are unable to provide - a user-friendly interface that gives users ofa range of literacy and education levels descriptive, personalized and
easily accessible information. However, at present most DTC users pay
for the service, and in doing so, fuel research efforts of the parent com-
panies offering these services. Although most researchers cannot indi-
vidually offer the same usability and customer support amenities as
23andMe.com, they are increasingly able to offer participants greater
levels of choice and control, aswell asmanage a diverse range of partic-
ipant preferences. The company Private Access (privateaccess.info) is
one such platform that seeks to provide participants with substantial
control over the uses of their data in research (Terry and Terry, 2011).
The platform allows researchers to search for potential study partici-
pants with great specificity because participants who use Private Access
enter their entire personal health records, and have control over both
individual portions of their personal health records as well as the
scope of researchers and research groups that the data is visible to.
Researchers can use Private Access to recruit participants, access this
private data by being granted “private access” by the participants, and
use the data in the records of recruited participants in applicable
research projects.
Private Access uses this dynamic negotiation approach to moder-
ate patient involvement in research repositories. The traditional prac-
tice of entering data into repositories often requires participants'
broad consent to authorize secondary use of their anonymized or
de-identified data. Although it may be impossible for participants to
fully know all potential future studies in which their data could be
used, refusal to agree to such broad use thus renders secondary
usage of their data an all or nothing decision (Fullerton and Lee,
2011). Private Access arguably overcomes this bottleneck by permit-
ting individual control over privacy and data sharing, much like social
sharing tools like Facebook.com. Some participants may choose to set
liberal privacy settings, permitting any researcher access to their data
in full for screening and eligibility purposes, while others may request
to be contacted about study eligibility after giving access permission
on a case-by-case basis. By giving participants this dynamic control,
Private Access supports broad consent, if that is what an individual
prefers, but it also gives participants the opportunity to choose the ac-
cess level with which they are most comfortable over time. It should
be noted that much like Facebook and other social-networking sites,
the definition of what is personally and culturally appropriate to
share is an evolving discussion and one that is likely to vary from per-
son to person. Tools such as Private Access, or the open-source Indivo
(indivohealth.org), can be tailored to provide culturally specific infor-
mation or utilize trusted community leaders as “guides” through the
decisions involved in selecting preferences. Data is emerging now re-
garding how tools such as these facilitate participant participation.
2.4. Public engagement through citizen science: direct participant
involvement tools
Increased public awareness of large volunteer registries, such as
the Love/Avon Army of women (armyofwomen.org) or Inspire 2
Live (inspire2live.com) can be considered a minimal form of public
engagement in the research process. Towards the other end of the
spectrum lies Genomera.com, a company that seeks to empower
and engage the public in research by giving them the opportunity to
be ‘citizen scientists’ who can design, conduct, and analyze their
own studies (Eolgin, 2010). Members of Genomera.com can develop
their own study designs (i.e., study creator), participate in the study
themselves, and post procedures for other community members to
participate in their study. Study participants then send their results
to the study creator for analysis. The openness of this community
enables participants to be recruited and studies to be completed much
quicker than the traditional research process.
Given the established conventions for peer review and controlled
research, the likelihood of the citizen scientists at Genomera.com
having their results published in scientific journals is presently slim.
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methods, the possibility offinding significant results, or creatingmethods
that can be replicated in other studies is possible. Furthermore, such citi-
zen science approaches are challenging existing paradigms about accept-
ed standards in research, finding their own distribution channels outside
of traditional dissemination strategies (CES4Health.info, 2012). Efforts,
such as Genomera.com, demonstrate the desire for people to play a larger
role in research. Whether through educating participants about studies
they participate in, returning study results (Beskow and Smolek, 2009),
or answering participants' questions, participants can become more
involved (Gust and Seifer, 2011). Involving participants could increase
the likelihood of future participation, adherence to study protocols, or
sharing positive research experiences with others.
3. Conclusion
There arewidespread changes occurring internationally in health care,
and all face common challenges of effective leverage of information tech-
nology, theneed for accurate clinical andhealth data, and the need for pri-
vacy protections (Collins, 2011; Meslin and Cho, 2010; U.K. E-Health
Records Failure Makes U.S. Plan Shine, 2011). The research enterprise
can utilize similar developments in order to keep up with changing
socio-cultural context that requires more engaged research participation
to be successful. If decisions are made and practices are built without
due diligence to public opinion, then the string of inefficiencies and
ethical questions will unnecessarily grow. We have observed resources
destroyed due to of lack of appropriate public engagement (Root, 2010).
We should look not only to public opinion, but also to the empowered
public by facilitating their engagement in the research process as key
stakeholders. Recruiting participants, protecting their privacy, and ensur-
ing informed consent should not be viewed as burdensome bottlenecks,
but rather as opportunities to engage, inform, and benefit the ultimate
end-user of all research, the public.
Using PCI in research is one approach to overcome these challenges by
leveraging new communication and facilitationmodes increasingly avail-
able through the on-line economy. From the informatics-based initiatives
we have presented, to the great successes of participant-centered organi-
zations like Love's Army of Women and Genetic Alliance, to participant-
driven social networking sites, the possibilities of an empowered public
are starting to be realized. Data are needed in a variety of settings to
testwhether and howPCI can facilitate and sustain research participation
across populations, particularly thosewith less access toweb-based tech-
nologies and whomay benefit the most. If we keep lessons learned from
community-based research, minority recruitment, decision support, and
other innovations, we can meet the goal of an active and invested com-
munity of research participants. With the current initiatives already in
development and use, we have crossed an important threshold of feasi-
bility testing and can now move into efficacy and effectiveness studies.
Research groups and funders can begin to make the choice to utilize
these tools and study the process along the way.
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